Peri-vascular Adipose Tissue Inflammation Evaluated Using Coronary CT Angiography

Exclusion Criteria

• •The participant may not enter the study if ANY of the following are known to apply:
• •1. Previous documented history of coronary artery disease requiring treatment. This includes any of the following:
• •Acute myocardial infarction Unstable angina Coronary revascularization procedure Clinically significant coronary artery disease diagnosed by invasive or non-invasive testing.
• •2. Known diabetes mellitus
• •3. Definite clinical indication for statin treatment (i.e. has either cholesterol \>6.5 mM, or cholesterol \>5.0 mM and QRISK score \>10%).
• •4. Treatment with aspirin, statin or any prescribed lipid modification therapy in 6 weeks before baseline CCTA
• •5. Atrial fibrillation (paroxysmal or persistent)
• •6. History of New York Heart Association (NYHA) Class III or IV heart failure within the past 12 months of consent.
• •7. Autoimmune disease requiring immunosuppressive therapy or systemic corticosteroid therapy
• •8. Active treatment with any anti-inflammatory agents (e.g. NSAIDs, corticosteroids)
• •9. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to screening with no detectable recurrence are allowed)
• •10. Contraindication for aspirin and/or statin therapy
• •11. Severe Chronic kidney disease (estimated glomerular filtration rate \< 30 mL/min/1.73 m² and/or serum creatinine \> 2.5 mg/dL or 220 µmol/l).
• •12. Hepatic dysfunction (aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] \> 3 × the upper limit of normal \[ULN\] measured on local labs in last 6 months)
• •13. Any clinically significant abnormality identified at the time of screening that, in the opinion of the Investigator, would preclude safe completion of the study.
• •14. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• •15. Participants who have participated in another research study involving a treatment intervention or an investigational product, in the past 12 weeks.
• •16. Patients unable to understand verbal or written English.
• •17. Contraindication to contract dye for CCTA.
• •18. Pregnancy